These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 22721889

  • 1. Lobular panniculitis and lipoatrophy of the thighs with interferon-ß1a for intramuscular injection in a patient with multiple sclerosis.
    Weise G, Hupp M, Kerstan A, Buttmann M.
    J Clin Neurosci; 2012 Sep; 19(9):1312-3. PubMed ID: 22721889
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
    Heinzerling L, Dummer R, Burg G, Schmid-Grendelmeier P.
    Eur J Dermatol; 2002 Sep; 12(2):194-7. PubMed ID: 11872423
    [Abstract] [Full Text] [Related]

  • 8. A case of septal panniculitis secondary to interferon treatment.
    Ozuguz P, Kacar SD, Karaca S, Tokyol C.
    Cutan Ocul Toxicol; 2014 Dec; 33(4):351-2. PubMed ID: 24641120
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
    Thouvenot E, Carlander B, Camu W.
    Expert Rev Neurother; 2012 Nov; 12(11):1283-91. PubMed ID: 23140228
    [Abstract] [Full Text] [Related]

  • 10. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P.
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
    Clin Neuropharmacol; 2008 Feb; 31(3):167-72. PubMed ID: 18520983
    [Abstract] [Full Text] [Related]

  • 14. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
    Serarslan G, Okuyucu E, Melek I, Hakverdi S, Duman T.
    Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
    [Abstract] [Full Text] [Related]

  • 15. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.
    J Neurol Sci; 2012 Jan 15; 312(1-2):97-101. PubMed ID: 21880336
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.